The Effect of Escitalopram in Treating Mild to Moderate Depressive Disorder and Improving the Quality of Life in Patients Undergoing Coronary Artery Bypass Grafting – a Double-Blind Randomized Clinical Trial Publisher



A Baradaran ABDOLVAHAB ; Mrk Ardakani Mohammad Reza KHODAIE ; Fs Bateni Fatemeh SADAT ; F Asadiankoohestani FATEMEH ; M Vahedi MOHSEN ; A Aein AFSANEH ; N Shahmansouri NAZILA ; G Sadighi GITA
Source: Frontiers in Psychiatry Published:2024

Abstract

Introduction: Chronic depression and anxiety can be a risk factor for coronary aArtery bypass grafting (CABG) and is an emerging factor after coronary artery disease when the patient is admitted to the hospital and after surgery. We aimed to assess the effect of Escitalopram in treating mild to moderate depressive disorder and improving the quality of life in patients undergoing CABG. Methods: In this randomized clinical trial, 50 patients undergoing CABG referred to Tehran Heart Hospital from January 2021 to May 2021 and were suffering from mild to moderate depression were randomly assigned to one of the two groups of Escitalopram or placebo. The level of depression was assessed based on Beck’s depression inventory and the quality-of-life status and its domains were assessed based on the SF-36 questionnaire in 2 groups. Measurements were obtained at baseline and at four and eight weeks after treatment. Chi-square, Fisher’s exact, paired, and Wilcoxon tests or ANOVA were used as appropriate. Results: There was no significant difference between the level of depression between the two study groups at baseline (P=0.312). There was no significant difference between the quality of life and its domains in the two study groups at baseline (P=0.607). However, the most important effect of Escitalopram was reducing depression scores in the intervention group at weeks 4 and 8 after treatment compared to the placebo group (P<0.001). The quality of life and its domains were significantly higher in the Escitalopram group eight weeks after treatment (P=0.004). The amount of drug side effects at 2 and 4 weeks after treatment had no significant difference between the groups (P>0.05). Conclusion: Escitalopram was effective in treating mild to moderate depressive disorder and improving quality of life in patients undergoing CABG. Clinical trial registration: https://irct.behdasht.gov.ir/, identifier IRCT20140126016374N2. © 2024 Elsevier B.V., All rights reserved.